Integrated Annual Report 2024

10 Associates and joint arrangements

Accounting policy

An associate is an entity over which dsm-firmenich has significant influence but no control or joint control, usually evidenced by a shareholding that entitles dsm-firmenich to between 20% and 50% of the voting rights. A joint venture is an entity over which dsm-firmenich has joint control and is entitled to its share of the net assets and liabilities.

Investments in associates and joint ventures are initially recognized at cost, including transaction costs. Subsequent to initial recognition, these investments are accounted for by the equity method, which involves recognition in the income statement of dsm-firmenich’s share of the associate’s or joint venture’s profit or loss for the year determined in accordance with the accounting policies of dsm-firmenich. Any other results at dsm-firmenich in relation to associated companies are recognized under Other results related to associates and joint ventures. dsm-firmenich’s interest in an associate or joint venture is carried in the balance sheet at its share in the net assets of the associate or joint venture together with goodwill paid on acquisition, less any impairment loss.

When dsm-firmenich’s share in the loss of an associate or joint venture exceeds the carrying amount of that entity, the carrying amount is reduced to zero. No further losses are recognized unless dsm-firmenich has responsibility for obligations relating to the entity.

Associates and joint ventures

The table ‘Carrying amount and share of profit of associates and joint ventures’ below analyses, in aggregate, the carrying amount and share of profit of associates and joint ventures. For acquisitions and divestments, see Note 3 Change in the scope of consolidation.

Carrying amount and share of profit of associates and joint ventures

 

 

2024

 

2023

 

 

MidCo Omega

 

Essential Labs

 

Other associates

 

JVs

 

Total

 

Total

Balance at 1 January

 

 

43

 

72

 

15

 

130

 

61

 

 

 

 

 

 

 

 

 

 

 

 

 

- Share of the profit of associates and joint ventures

 

(3)

 

4

 

1

 

(12)

 

(10)

 

(6)

- Other comprehensive income

 

 

 

 

 

 

(3)

- Capital payments

 

 

 

11

 

6

 

17

 

5

- Dividends received

 

 

(1)

 

(8)

 

 

(9)

 

(2)

- Acquisitions

 

 

 

 

 

 

74

- Disposals

 

 

 

 

 

 

- Other consolidation change

 

159

 

 

19

 

30

 

208

 

- Other

 

3

 

2

 

1

 

 

6

 

1

Balance at 31 December

 

159

 

48

 

96

 

39

 

342

 

130

The other consolidation change relating to MidCo Omega relates to the divestment of the Marine Lipids business to the KD Pharma group. As part of that transaction, dsm-firmenich has obtained a minority stake of 29% in KD Pharma’s parent company MidCo Omega GmbH.

Key figures of main associates on a 100% basis

 

 

MidCo Omega

 

Essential Labs

 

 

2024

 

2023

 

2024

 

2023

Current assets

 

325

 

 

19

 

17

Non-current assets

 

395

 

 

14

 

13

Current liabilities

 

71

 

 

2

 

4

Non-current liabilities

 

249

 

 

7

 

8

Net assets (100% basis)

 

400

 

 

24

 

18

of which Non-controlling interest

 

1

 

 

 

Attributable to investee’s shareholders

 

399

 

 

24

 

18

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Summarized statement of profit or loss

 

 

 

 

 

 

 

 

Revenue (net sales)

 

31

 

 

72

 

52

Profit for the year (continuing operations)

 

(9)

 

 

7

 

6

Other comprehensive income

 

 

 

 

Total comprehensive income

 

(9)

 

 

7

 

6

of which Non-controlling interest

 

 

 

 

Attributable to investee’s shareholders

 

(9)

 

 

7

 

6

Joint operations

The operations Veramaris® and Avansya are accounted for in accordance with IFRS 11 for joint operations. dsm-firmenich therefore recognizes their amounts for the assets, liabilities, revenues and expenses in accordance with the contractual entitlement and obligations of dsm-firmenich, see also Note 1 General information.

Topic filter

Results